PMID- 17448417
OWN - NLM
STAT- MEDLINE
DCOM- 20070612
LR  - 20220223
IS  - 1532-8414 (Electronic)
IS  - 1071-9164 (Linking)
VI  - 13
IP  - 3
DP  - 2007 Apr
TI  - High serum level of pentosidine, an advanced glycation end product (AGE), is a 
      risk factor of patients with heart failure.
PG  - 199-206
AB  - BACKGROUND: Pentosidine, one of the advanced glycation end products (AGE), is 
      generated by nonenzymatic glycation and oxidation of proteins. The receptor of 
      AGE (RAGE) is expressed in a variety of tissue, and interaction of AGE with RAGE 
      induces oxidative stress and activation of intracellular signaling, causing 
      production of cytokines and mediators of inflammation. We investigated whether 
      serum pentosidine is a risk factor for heart failure. METHODS AND RESULTS: Serum 
      pentosidine concentration was measured in 141 patients with heart failure and 18 
      control subjects by a competitive enzyme-linked immunosorbent assay. Patients 
      were prospectively followed during a median follow-up period of 479 days with end 
      points of cardiac death or rehospitalization. Serum concentration of pentosidine 
      was significantly higher in New York Heart Association (NYHA) Class III/IV 
      patients than in NYHA class I/II patients (P < .0001). Serum pentosidine was also 
      higher in patients with cardiac events than in event-free patients (P < .001). In 
      the univariate Cox proportional hazard analysis, age, NYHA class, pentosidine, 
      creatinine, uric acid, B-type natriuretic peptide, left ventricular end-systolic 
      volume, and left ventricular mass were significant risk factors to predict 
      cardiac events. In the multivariate Cox analysis, serum pentosidine concentration 
      was an independent risk factor for cardiac events (hazard ratio 1.88, 95% 
      confidence interval 1.23-2.69, P = .002). The highest 4th quartile of pentosidine 
      was associated with the highest risk of cardiac events (4.52-fold). CONCLUSIONS: 
      Serum pentosidine concentration is an independent prognostic factor for heart 
      failure, and this new marker may be useful for risk stratification of patients 
      with heart failure. Patients were divided into 4 groups based on the serum 
      pentosidine levels.
FAU - Koyama, Yo
AU  - Koyama Y
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine, Yamagata, Japan.
FAU - Takeishi, Yasuchika
AU  - Takeishi Y
FAU - Arimoto, Takanori
AU  - Arimoto T
FAU - Niizeki, Takeshi
AU  - Niizeki T
FAU - Shishido, Tetsuro
AU  - Shishido T
FAU - Takahashi, Hiroki
AU  - Takahashi H
FAU - Nozaki, Naoki
AU  - Nozaki N
FAU - Hirono, Osamu
AU  - Hirono O
FAU - Tsunoda, Yuichi
AU  - Tsunoda Y
FAU - Nitobe, Joji
AU  - Nitobe J
FAU - Watanabe, Tetsu
AU  - Watanabe T
FAU - Kubota, Isao
AU  - Kubota I
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Card Fail
JT  - Journal of cardiac failure
JID - 9442138
RN  - 0 (Biomarkers)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Diuretics)
RN  - 73K4184T59 (Digoxin)
RN  - 94ZLA3W45F (Arginine)
RN  - BJ4I2X2CQJ (pentosidine)
RN  - K3Z4F929H6 (Lysine)
SB  - IM
CIN - J Card Fail. 2008 Sep;14(7):626; author reply 627-8. PMID: 18722329
MH  - Aged
MH  - Arginine/*analogs & derivatives/blood
MH  - Biomarkers/blood
MH  - Cardiotonic Agents/therapeutic use
MH  - Case-Control Studies
MH  - Comorbidity
MH  - Diabetes Complications/epidemiology
MH  - Digoxin/therapeutic use
MH  - Diuretics/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*blood/classification/diagnosis/drug therapy/*epidemiology
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Japan/epidemiology
MH  - Lysine/*analogs & derivatives/blood
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Renal Insufficiency/epidemiology
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Survival Analysis
EDAT- 2007/04/24 09:00
MHDA- 2007/06/15 09:00
CRDT- 2007/04/24 09:00
PHST- 2006/05/31 00:00 [received]
PHST- 2006/09/30 00:00 [revised]
PHST- 2006/11/21 00:00 [accepted]
PHST- 2007/04/24 09:00 [pubmed]
PHST- 2007/06/15 09:00 [medline]
PHST- 2007/04/24 09:00 [entrez]
AID - S1071-9164(06)01252-8 [pii]
AID - 10.1016/j.cardfail.2006.11.009 [doi]
PST - ppublish
SO  - J Card Fail. 2007 Apr;13(3):199-206. doi: 10.1016/j.cardfail.2006.11.009.